|
1
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar
|
|
2
|
Malumbres M: Cell cycle-based therapies
move forward. Cancer Cell. 22:419–420. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yu Q, Sicinska E, Geng Y, et al:
Requirement for CDK4 kinase function in breast cancer. Cancer Cell.
9:23–32. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Puyol M, Martin A, Dubus P, et al: A
synthetic lethal interaction between K-Ras oncogenes and Cdk4
unveils a therapeutic strategy for non-small cell lung carcinoma.
Cancer Cell. 18:63–73. 2010. View Article : Google Scholar
|
|
5
|
Hu MG, Deshpande A, Enos M, et al: A
requirement for cyclin-dependent kinase 6 in thymocyte development
and tumorigenesis. Cancer Res. 69:810–818. 2009. View Article : Google Scholar
|
|
6
|
Blagden S and de Bono J: Drugging cell
cycle kinases in cancer therapy. Curr Drug Targets. 6:325–335.
2005. View Article : Google Scholar
|
|
7
|
Malumbres M, Sotillo R, Santamaria D, et
al: Mammalian cells cycle without the D-type cyclin-dependent
kinases Cdk4 and Cdk6. Cell. 118:493–504. 2004. View Article : Google Scholar
|
|
8
|
Collins I and Garrett MD: Targeting the
cell division cycle in cancer: CDK and cell cycle checkpoint kinase
inhibitors. Curr Opin Pharmacol. 5:366–373. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu G, Gandara DR, Lara PN Jr, et al: A
Phase II trial of flavopiridol (NSC #649890) in patients with
previously untreated metastatic androgen-independent prostate
cancer. Clin Cancer Res. 10:924–928. 2004.
|
|
10
|
Lapenna S and Giordano A: Cell cycle
kinases as therapeutic targets for cancer. Nat Rev Drug Discov.
8:547–566. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fry DW, Harvey PJ, Keller PR, et al:
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991
and associated antitumor activity in human tumor xenografts. Mol
Cancer Ther. 3:1427–1438. 2004.
|
|
12
|
Toogood PL, Harvey PJ, Repine JT, et al:
Discovery of a potent and selective inhibitor of cyclin-dependent
kinase 4/6. J Med Chem. 48:2388–2406. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wiedemeyer WR, Dunn IF, Quayle SN, et al:
Pattern of retinoblastoma pathway inactivation dictates response to
CDK4/6 inhibition in GBM. Proc Natl Acad Sci USA. 107:11501–11506.
2010. View Article : Google Scholar
|
|
14
|
Finn RS, Dering J, Conklin D, et al: PD
0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially
inhibits proliferation of luminal estrogen receptor-positive human
breast cancer cell lines in vitro. Breast Cancer Res. 11:R772009.
View Article : Google Scholar
|
|
15
|
Michaud K, Solomon DA, Oermann E, et al:
Pharmacologic inhibition of cyclin-dependent kinases 4 and 6
arrests the growth of glioblastoma multiforme intracranial
xenografts. Cancer Res. 70:3228–3238. 2010. View Article : Google Scholar
|
|
16
|
Baughn LB, Di Liberto M, Wu K, et al: A
novel orally active small molecule potently induces G1 arrest in
primary myeloma cells and prevents tumor growth by specific
inhibition of cyclin-dependent kinase 4/6. Cancer Res.
66:7661–7667. 2006. View Article : Google Scholar
|
|
17
|
Liu F and Korc M: Cdk4/6 inhibition
induces epithelial-mesenchymal transition and enhances invasiveness
in pancreatic cancer cells. Mol Cancer Ther. 11:2138–2148. 2012.
View Article : Google Scholar
|
|
18
|
Cen L, Carlson BL, Schroeder MA, et al:
p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase
inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol.
14:870–881. 2012. View Article : Google Scholar
|
|
19
|
Roberts PJ, Bisi JE, Strum JC, et al:
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer
therapy. J Natl Cancer Inst. 104:476–487. 2012. View Article : Google Scholar
|
|
20
|
Schwartz GK, LoRusso PM, Dickson MA, et
al: Phase I study of PD 0332991, a cyclin-dependent kinase
inhibitor, administered in 3-week cycles (Schedule 2/1). Br J
Cancer. 104:1862–1868. 2011. View Article : Google Scholar
|
|
21
|
Flaherty KT, Lorusso PM, Demichele A, et
al: Phase I, dose-escalation trial of the oral cyclin-dependent
kinase 4/6 inhibitor PD 0332991, administered using a 21-day
schedule in patients with advanced cancer. Clin Cancer Res.
18:568–576. 2012. View Article : Google Scholar
|
|
22
|
Leonard JP, LaCasce AS, Smith MR, et al:
Selective CDK4/6 inhibition with tumor responses by PD0332991 in
patients with mantle cell lymphoma. Blood. 119:4597–4607. 2012.
View Article : Google Scholar
|
|
23
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
24
|
Cole AM, Myant K, Reed KR, et al: Cyclin
D2-cyclin-dependent kinase 4/6 is required for efficient
proliferation and tumorigenesis following Apc loss. Cancer Res.
70:8149–8158. 2010. View Article : Google Scholar
|
|
25
|
Garneau H, Paquin MC, Carrier JC and
Rivard N: E2F4 expression is required for cell cycle progression of
normal intestinal crypt cells and colorectal cancer cells. J Cell
Physiol. 221:350–358. 2009. View Article : Google Scholar
|
|
26
|
Li B, Gao S, Wei F, Bellail AC, Hao C and
Liu T: Simultaneous targeting of EGFR and mTOR inhibits the growth
of colorectal carcinoma cells. Oncol Rep. 28:15–20. 2012.
|
|
27
|
Wei F, Liu Y, Bellail AC, et al: K-Ras
mutation-mediated IGF-1-induced feedback ERK activation contributes
to the rapalog resistance in pancreatic ductal adenocarcinomas.
Cancer Lett. 322:58–69. 2012. View Article : Google Scholar
|
|
28
|
Bellail AC, Olson JJ, Yang X, Chen ZJ and
Hao C: A20 ubiquitin ligase-mediated polyubiquitination of RIP1
inhibits caspase-8 cleavage and TRAIL-induced apoptosis in
glioblastoma. Cancer Discov. 2:140–155. 2012. View Article : Google Scholar
|
|
29
|
Wang Q, Wei F, Li C, et al: Combination of
mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase
activity and suppresses the progression of colorectal carcinoma.
PLoS One. 8:e731752013. View Article : Google Scholar
|
|
30
|
Wang Q, Wei F, Lv G, et al: The
association of TP53 mutations with the resistance of colorectal
carcinoma to the insulin-like growth factor-1 receptor inhibitor
picropodophyllin. BMC Cancer. 13:5212013. View Article : Google Scholar
|
|
31
|
Rubin SM: Deciphering the retinoblastoma
protein phosphorylation code. Trends Biochem Sci. 38:12–19. 2013.
View Article : Google Scholar
|
|
32
|
Meyerhardt JA and Mayer RJ: Systemic
therapy for colorectal cancer. N Engl J Med. 352:476–487. 2005.
View Article : Google Scholar : PubMed/NCBI
|
